2022
CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression
Zhang M, Liu ZZ, Aoshima K, Cai WL, Sun H, Xu T, Zhang Y, An Y, Chen JF, Chan LH, Aoshima A, Lang SM, Tang Z, Che X, Li Y, Rutter SJ, Bossuyt V, Chen X, Morrow JS, Pusztai L, Rimm DL, Yin M, Yan Q. CECR2 drives breast cancer metastasis by promoting NF-κB signaling and macrophage-mediated immune suppression. Science Translational Medicine 2022, 14: eabf5473. PMID: 35108062, PMCID: PMC9003667, DOI: 10.1126/scitranslmed.abf5473.Peer-Reviewed Original ResearchConceptsBreast cancer metastasisReticuloendotheliosis viral oncogene homolog ACancer metastasisImmune suppressionM2 macrophagesWorse metastasis-free survivalMetastatic breast cancerMetastasis-free survivalV-rel avian reticuloendotheliosis viral oncogene homolog ACancer-related deathPrimary breast tumorsMultiple mouse modelsNF-κB signalingImmunocompetent settingNuclear factor-κB family membersMetastasis-promoting genesDistant metastasisMetastatic sitesPrimary tumorEffective therapyBreast cancerMetastasis treatmentMouse modelBreast tumorsMetastasis
2010
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer
Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2010, 107: 10208-10213. PMID: 20479250, PMCID: PMC2890442, DOI: 10.1073/pnas.0907011107.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Agents, HormonalBase SequenceBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesDNA PrimersFemaleGene Expression ProfilingHumansMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesMutationNeoplasms, Hormone-DependentOligonucleotide Array Sequence AnalysisPhosphatidylinositol 3-KinasesPrognosisProteinsProto-Oncogene Proteins c-aktReceptor, ErbB-2Receptors, EstrogenSignal TransductionSirolimusTamoxifenTOR Serine-Threonine KinasesTranscription FactorsConceptsBreast cancerPIK3CA mutationsClinical outcomesEstrogen receptor-positive breast cancerReceptor-positive breast cancerGene signaturePIK3CA mutation statusPI3K/mTOR inhibitorBetter clinical outcomesPI3K/mTOR inhibitionHuman breast cancerBC cell linesPIK3CA mutant breast cancersCommon genetic aberrationsTamoxifen monotherapyBetter prognosisMTOR inhibitorsBetter outcomesMutation statusMTOR inhibitionPathway activationExperimental modelGenetic aberrationsPrognosisCell lines
2004
Breast cancer biomarkers and molecular medicine: part II
Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. Breast cancer biomarkers and molecular medicine: part II. Expert Review Of Molecular Diagnostics 2004, 4: 169-188. PMID: 14995904, DOI: 10.1586/14737159.4.2.169.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesDNADrug Resistance, MultipleEndopeptidasesFemaleGene Expression ProfilingGenes, Tumor SuppressorHumansOncogenesPharmacogeneticsPrognosisProto-Oncogene Proteins c-bcl-2Receptors, EstrogenReceptors, ProgesteroneTelomeraseTranscription FactorsConceptsInvasion-associated proteinsMolecular medicineTumor suppressor geneTranscriptional profilingTranscription factorsDNA repairCell adhesion moleculeDrug resistance proteinsGenomic microarraysApoptosis regulatorSuppressor geneHormone receptor proteinsReceptor proteinBreast cancer biomarkersResistance proteinCancer biomarkersProteinBreast cancer prognostic factorsAdhesion moleculesCancer prognostic factorsPrognostic factorsTherapy responseGenesMethylationTelomeraseExpression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer
Pusztai L, Krishnamurti S, Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer. Cancer Investigation 2004, 22: 248-256. PMID: 15199607, DOI: 10.1081/cnv-120030213.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarrier ProteinsCell DeathChemotherapy, AdjuvantDNA-Binding ProteinsDoxorubicinFemaleHumansImmunohistochemistryMiddle AgedNeoadjuvant TherapyPredictive Value of TestsPrognosisProto-Oncogene Proteins c-bcl-2Transcription FactorsTreatment OutcomeConceptsComplete pathological responsePathological responseBcl-2 expressionNeoplastic cellsBcl-2Breast cancerTissue specimensSubsequent pathological responsesAdvanced breast cancerBAG-1Breast epithelial cellsBAG-1 expressionExploratory pilot studyPrechemotherapy specimensNeoadjuvant chemotherapyClinical responseResidual tumorCytotoxic therapyPosttreatment specimensAnti-apoptotic proteinsPreoperative doxorubicinChemotherapyCytoplasmic stainingIndividual tumorsBreast tissue
2003
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 2003, 9: 5652-9. PMID: 14654548.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCell Cycle ProteinsCOP9 Signalosome ComplexCyclin-Dependent Kinase Inhibitor p27DNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticGenes, Tumor SuppressorHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMiddle AgedPeptide HydrolasesReceptor, ErbB-2Receptors, EstrogenSurvival AnalysisTime FactorsTranscription FactorsTumor Suppressor ProteinsConceptsNode-negative breast cancerAdjacent normal tissuesInvasive breast carcinomaBreast cancerJab1 overexpressionNormal tissuesBreast carcinomaAdjuvant systemic therapyDisease-free survivalIndependent prognostic factorInvasive breast cancerLow nuclear gradeBreast cancer tissuesExpression levelsProtein-1 expressionBreast tumor tissuesWestern blot analysisDomain-binding protein 1Patient agePrognostic factorsSystemic therapyPrognostic significanceTumor sizeNuclear gradeInvasive tumors